Bio Sidus Sa
Clinical trials sponsored by Bio Sidus Sa, explained in plain language.
-
New biosimilar for fabry disease shows promise in small switch study
Disease control CompletedThis study tested a new enzyme replacement drug (AGA BETA BS) for Fabry disease, a rare genetic disorder. It involved 20 adults who were already stable on the standard treatment, Fabrazyme. The goal was to see if switching to the new drug kept their disease marker (Lyso-Gb3) at s…
Phase: PHASE3 • Sponsor: Bio Sidus SA • Aim: Disease control
Last updated Jun 15, 2026 19:08 UTC
-
New version of fabry drug tested against Brand-Name in healthy volunteers
Knowledge-focused CompletedThis early study tested whether a new version of the enzyme replacement drug agalsidase beta (made by Biosidus) works similarly to the approved drug Fabrazyme. Twenty-four healthy men received a single infusion of one of the two drugs. Researchers measured how the drug moved thro…
Phase: PHASE1 • Sponsor: Bio Sidus SA • Aim: Knowledge-focused
Last updated Jun 22, 2026 11:56 UTC